Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Flu cases are spiking earlier than usual. What you need to know. - 2Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- 3Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- 4Netflix is releasing a documentary on Elizabeth Smart. What to know about her kidnapping, rescue and where she is now.
- 5Overlooked infertility care should be part of national health services, says WHO
- Productive CRM Programming for Client Relationship The executives
- Black Friday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- Remarkable Spots for Hot Air Swelling All over The Planet
- Become the best at Discussion: 6 Procedures for Progress
- Chinese mega embassy could bring security advantages, says No 10
- The Most Vital Crossroads in Olympic History
- Phenomenal Web-based MBA Stages for Proficient Headway
- Grammy nominations 2026: Full list of nominees in every major category, including Album of the Year and Best New Artist
- The Fate of Mechanical technology: 5 Headways Forming Tomorrow
